PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a ...

Researchers conducted a post hoc, retrospective, cross-sectional analysis of 182 patients with recurrent prostate cancer ...

Researchers conducted a retrospective study using data from 182 subjects with high-risk recurrent prostate cancers.

Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease missed by conventional imaging, investigators report.

Nearly half of high-risk prostate cancer patients classified as nonmetastatic by traditional imaging show metastases when ...

Researchers at UCLA have unveiled startling findings using PSMA-PET imaging that reveal nearly half of patients diagnosed ...

This advanced imaging technology plays a critical role in redefining how prostate cancer is staged. PSMA-PET imaging uses tiny amounts of radioactive “tracers,” called radiotracers, that binds to ...

Advanced imaging reveals hidden metastases in high-risk prostate cancer cases, offering new insights for better diagnosis and treatment strategies.

PSMA PET CT showed a solitary pelvic node with no prostate fossa recurrence. The patient underwent salvage radiotherapy including both fossa and pelvic node fields. PSA continued to rise ...

PSMA-PET imaging has higher sensitivity than conventional imaging and can detect radiorecurrent prostate cancer at lower PSA levels. PSMA-PET imaging can detect radiorecurrent prostate cancer ...

Jacob E. Berchuck, MD, discusses how a new epigenomic platform may influence the accessibility of PSMA-based therapies, ...

Lantheus (LNTH) is a strong buy with a dominant market position in radiopharmaceuticals and promising growth in Alzheimer's ...